GALECTIN THERAPEUTICS INC — Director's Dealing 2018

Apr 6, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2018-04-04

Reporting Person: CALLICUTT JACK W (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-04-04	Common Stock	M	3349	$.87	Acquired	4609	Direct
2018-04-04	Common Stock	S	3349	$5.00	Disposed	1260	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-04	Stock option (right to buy)	$.87	M	3349	Disposed	2026-12-03	Common Stock (3349)	Direct

Footnotes

F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018.

F2: The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017.